Sugi Predict

Sugi Predict / Compounds / SCHEMBL238334

SCHEMBL238334

SCHEMBL238334

COc1ccc(C2=CCN(Cc3ccccc3)CC2)cc1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.66
▸ KMT2A Q03164 2/20 0.66
▸ HTR1A P08908 5/20 0.61
▸ DRD2 P14416 5/20 0.61
▸ SIGMAR1 Q99720 2/20 0.61
▸ KDM4E B2RXH2 4/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ MAPT P10636 2/20 0.57
▸ GAA P10253 1/20 0.57
▸ POLB P06746 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ DRD4 P21917 1/20 0.52
▸ HDAC4 P56524 1/20 0.52
▸ NAMPT P43490 1/20 0.52
▸ HTR2A P28223 1/20 0.52
▸ MAPK1 P28482 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL19066024 0.99 MEN1 (0.65) MEN1KMT2AHTR1ADRD2SIGMAR1
Tetrahydrofuran SCHEMBL28260118 0.92 MEN1 (0.57) MEN1KMT2AHTR1ADRD2SIGMAR1
SCHEMBL7969931 0.90 MEN1 (0.65) MEN1KMT2AHTR1ADRD2SIGMAR1
SCHEMBL4827185 0.87 MEN1 (0.71) MEN1KMT2AHTR1ADRD2SIGMAR1
Hydrochloric Acid SCHEMBL6288085 0.86 MEN1 (0.69) MEN1KMT2AHTR1ADRD2SIGMAR1
SCHEMBL2395803 0.85 LMNA (0.60) MEN1KMT2AHTR1ADRD2SIGMAR1
SCHEMBL6585625 0.85 DRD4 (0.63) MEN1KMT2AHTR1ADRD2SIGMAR1
SCHEMBL2395932 0.85 DRD4 (0.67) HTR1ADRD2SIGMAR1GAADRD4
SCHEMBL8214501 0.85 NPC1 (0.56) MEN1KMT2AHTR1ADRD2SIGMAR1
SCHEMBL2471217 0.84 KMT2A (0.58) MEN1KMT2AHTR1ADRD2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
US-20210121453-A1 SELECTIVE NR2B ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2021-04-29 — — US disclosed
US-20210121453-A1 SELECTIVE NR2B ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2021-04-29 — — US disclosed
US-20200163949-A1 SELECTIVE NR2B ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2020-05-28 — — US disclosed
US-20200163949-A1 SELECTIVE NR2B ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2020-05-28 — — US disclosed
US-20190314358-A1 SELECTIVE NR2B ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2019-10-17 — — US disclosed
US-20190314358-A1 SELECTIVE NR2B ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2019-10-17 — — US disclosed
US-20190117638-A1 SELECTIVE NR2B ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2019-04-25 — — US disclosed
EP-2120572-A1 SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT Janssen Pharmaceutica, N.V. (BE) 2009-11-25 — — EP disclosed
WO-2008079255-A1 SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-03 — — WO disclosed
WO-2008079255-A1 SYNTHESIS OF UNSATURATED PIPERIDINES FROM PIPERIDONES WITH A SILYL REAGENT JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-03 — — WO disclosed
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 — — US disclosed
EP-0863875-B1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY HOFFMANN LA ROCHE (CH) 2003-06-04 — — EP disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 — — WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 — — US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 — — US disclosed
EP-0863875-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1998-09-16 — — EP disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS MEN1 4681/4885KMT2A 4093/4885HTR1A 4719/4885
US-20210121453-A1 SELECTIVE NR2B ANTAGONISTS GRIN2B, GRIN2A, GRIN3A MEN1 4538/4885KMT2A 2824/4885HTR1A 147/4885
US-20190117638-A1 SELECTIVE NR2B ANTAGONISTS GRIN2B, GRIN2A, GRIN3A MEN1 4538/4885KMT2A 2824/4885HTR1A 147/4885
US-20190314358-A1 SELECTIVE NR2B ANTAGONISTS GRIN2B, GRIN2A, GRIN3A MEN1 4538/4885KMT2A 2824/4885HTR1A 147/4885
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 MEN1 2561/4885KMT2A 2702/4885HTR1A 1397/4885
US-20200163949-A1 SELECTIVE NR2B ANTAGONISTS GRIN2B, GRIN2A, GRIN3A MEN1 4538/4885KMT2A 2824/4885HTR1A 147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.